Shilpa Antibiotics Ltd was incorporated as a Private Limited Company
in November 1987. The commercial production of the Company had
started in November 1989. The Company was initially producing
Trimethoprim IP/BP, an antibiotic bulk drug. The technology for the
bulk drug was developed in house. During the first year of its
operation the Company had installed production facilities to
manufacture Trimethoprim Apart from selling on its own, the Company
had also started manufacturing the product for other reputed
Companies like Eskayef Limited, Bombay Drugs
and Pharmas Limited, Bombay Drug House Ltd., US Vitamins Ltd, Sandoz
India Ltd etc for their export commitments.
During 1992, the Company had installed production facilities for
manufacture of Sodium Methoxide. The technology for the same had
also been developed in house. During the same year the Company
secured Export orders from Stellar Exports Limited, Glaxo Limited and
Limited for Trimethoprim. Since then the company has started
exporting on its own. The Company thus started manufacturing for
both export and domestic markets since 1992. It has obtained World
Health Organisation-Good Manufacturing Practices (GMP) Certificate.
It has also been exporting its products to hard currency areas.
The Company now proposes to embark upon an expansion project which
involves the addition of one more bulk drug to its existing product
range viz; Norfloxcin and expansion of the production capacity of the
existing product of the Company viz; Sodium Methoxide and
Trimethoprim. The Company also proposes to manufacture 1-Methyl
Amino-1-Methyl Thio-2-Nitro Ethane, a drug intermediate, used in the
manufacture of Ranitidine, an anti-ulcer drug. To raise the necessary
resources to finance the expansion project of the Company, the Company
was converted into a Public Limited Company in November 1993.
As the company's sales are comparatively more in the September to
March period, therefore, to reduce the administrative bottlenecks in
the timely preparation of annual results, the company changed its
accounting year from March end to September end.
Objects of the Company
The relevant objects of the company as set out in the memorandum of
association of the company are :
1. To carry on in India or elsewhere the industry, trade or business
of manufacturers, Traders, Dealers, Agents, Suppliers, Licensors,
Licensees, Loan Licenses, Importers, Exporters, Consultants,
Discoverers, Inventors, and Producers of Drugs, Bulk Drugs,
Pharmaceuticals, Pharmaceutical Formulations, Alcohol, Bended
Preparations, and general medicinal preparation and or their
by-products and packing and re-packing of the above.
-Shilpa Medicare Ltd has entered into a memorandum of understanding
(MoU) with LOBA Finchemie AG, Austria, to acquire 100% shares of LOBA
in an all-cash deal.
- The Company has splits its face value from Rs10/- to Rs2/-.
-Shilpa Medicare Ltd has informed that the Board of Director of the
Company has co-opted Mr. Sunki Rajendra reddy S/o. Mr Rajeshwara
Reddy as an Additional Director.
-Shilpa Medicare Ltd has informed that the Board of Directors of the
Company has co-opted Mr. N P S Shinh S/o. Mr. S Prithipal Singh Shinh
as an Additional Director.
- Shilpa Medicare Ltd has informed that the Company has signed a MOU
to form a joint venture company to manufacture drugs and
pharmaceuticals with ICE S.r.l. and PCA S.p.a. of Italy.